Literature DB >> 22174375

Alum adjuvant: some of the tricks of the oldest adjuvant.

Mirjam Kool1,2, Kaat Fierens2, Bart N Lambrecht1,2.   

Abstract

Alum has been the most widely used adjuvant for over 80 years. Although there have been searches for alternative adjuvants, aluminium-containing adjuvants will continue to be used for many years due to their good track record of safety, low cost and adjuvanticity with a variety of antigens. For infections that can be prevented by induction of serum antibodies, aluminium-containing adjuvants formulated under optimal conditions are the adjuvants of choice. There are also some limitations of aluminium-containing adjuvants, which include local reactions, augmentation of IgE antibody responses, ineffectiveness for some antigens and inability to augment cell-mediated immune responses, especially cytotoxic T-cell responses. In this review, we describe the current knowledge regarding the mechanisms (both cellular and molecular) by which alum employs its adjuvant effect, although the final mechanism is not yet well-defined. Furthermore, we discuss how alum's adjuvanticity could be improved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22174375     DOI: 10.1099/jmm.0.038943-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  91 in total

Review 1.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

2.  The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells.

Authors:  Simone Schüller; Lukas Wisgrill; Kambis Sadeghi; Erich Gindl; Hanns Helmer; Peter Husslein; Angelika Berger; Andreas Spittler; Elisabeth Förster-Waldl
Journal:  Pediatr Res       Date:  2016-04-08       Impact factor: 3.756

Review 3.  Old and new adjuvants for hepatitis B vaccines.

Authors:  Geert Leroux-Roels
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

4.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

5.  Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Authors:  Jan Tavernier; Sarah Gerlo; Bram Van Den Eeckhout; Lien Van Hoecke; Elianne Burg; Sandra Van Lint; Frank Peelman; Niko Kley; Gilles Uzé; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2020-07-23       Impact factor: 7.344

6.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination.

Authors:  Hok Hei Tam; Mariane B Melo; Myungsun Kang; Jeisa M Pelet; Vera M Ruda; Maria H Foley; Joyce K Hu; Sudha Kumari; Jordan Crampton; Alexis D Baldeon; Rogier W Sanders; John P Moore; Shane Crotty; Robert Langer; Daniel G Anderson; Arup K Chakraborty; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-04       Impact factor: 11.205

Review 7.  Vaccination against atherosclerosis.

Authors:  Kouji Kobiyama; Ryosuke Saigusa; Klaus Ley
Journal:  Curr Opin Immunol       Date:  2019-03-29       Impact factor: 7.486

8.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

9.  In Staphylococcus aureus, the Particulate State of the Cell Envelope Is Required for the Efficient Induction of Host Defense Responses.

Authors:  ByungHyun Kim; TingTing Jiang; Jun-Hyun Bae; Hye Su Yun; Seong Han Jang; Jung Hyun Kim; Jae Deog Kim; Jin-Hoe Hur; Kensuke Shibata; Kenji Kurokawa; Yunjin Jung; Andreas Peschel; Taeok Bae; Bok Luel Lee
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

10.  The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.

Authors:  Yun Hu; Daniel Smith; Evan Frazier; Reece Hoerle; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2016-08-18       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.